119 related articles for article (PubMed ID: 10494754)
21. Treatment of upper-extremity deep vein thrombosis.
Rathbun SW; Stoner JA; Whitsett TL
J Thromb Haemost; 2011 Oct; 9(10):1924-30. PubMed ID: 21838756
[TBL] [Abstract][Full Text] [Related]
22. Risk factors and recurrence rate of primary deep vein thrombosis of the upper extremities.
Martinelli I; Battaglioli T; Bucciarelli P; Passamonti SM; Mannucci PM
Circulation; 2004 Aug; 110(5):566-70. PubMed ID: 15262837
[TBL] [Abstract][Full Text] [Related]
23. Should patients with deep vein thrombosis alone be treated as those with concomitant asymptomatic pulmonary embolism? A prospective study.
Monreal M; Büller H; Lensing AW; Bonet M; Roncales J; Muchart J; Fraile M
Thromb Haemost; 2002 Dec; 88(6):938-42. PubMed ID: 12529742
[TBL] [Abstract][Full Text] [Related]
24. Deep venous thrombosis in children and adolescents.
Levy ML; Granville RC; Hart D; Meltzer H
J Neurosurg; 2004 Aug; 101(1 Suppl):32-7. PubMed ID: 16206969
[TBL] [Abstract][Full Text] [Related]
25. [Low molecular weight heparin versus unfractionated heparin in the treatment of deep vein thrombosis].
Moreno-Palomares JJ; Fisac-Herrero RM; Herrero-Domingo A; Ferreira-Pasos EM; Grasa J; Reverte-Cejudo D
An Med Interna; 2001 Jul; 18(7):364-8. PubMed ID: 11534421
[TBL] [Abstract][Full Text] [Related]
26. Home treatment of deep venous thrombosis with low molecular weight heparin: Long-term incidence of recurrent venous thromboembolism.
Grau E; Tenias JM; Real E; Medrano J; Ferrer R; Pastor E; Selfa S
Am J Hematol; 2001 May; 67(1):10-4. PubMed ID: 11279651
[TBL] [Abstract][Full Text] [Related]
27. Outpatient treatment of venous thromboembolism with low-molecular-weight heparin: an economic evaluation.
Huse DM; Cummins G; Taylor DC; Russell MW
Am J Manag Care; 2002 Jan; 8(1 Suppl):S10-6. PubMed ID: 11822346
[TBL] [Abstract][Full Text] [Related]
28. Once-daily subcutaneous dalteparin, a low molecular weight heparin, for the initial treatment of acute deep vein thrombosis.
Fiessinger JN; Lopez-Fernandez M; Gatterer E; Granqvist S; Kher A; Olsson CG; Söderberg K
Thromb Haemost; 1996 Aug; 76(2):195-9. PubMed ID: 8865530
[TBL] [Abstract][Full Text] [Related]
29. Randomized, placebo-controlled trial of dalteparin for the prevention of venous thromboembolism in acutely ill medical patients.
Leizorovicz A; Cohen AT; Turpie AG; Olsson CG; Vaitkus PT; Goldhaber SZ;
Circulation; 2004 Aug; 110(7):874-9. PubMed ID: 15289368
[TBL] [Abstract][Full Text] [Related]
30. [Venous thromboembolism associated with long-term use of central venous catheters in cancer patients].
Debourdeau P; Chahmi DK; Zammit C; Farge-Bancel D
Pathol Biol (Paris); 2008 Jun; 56(4):211-9. PubMed ID: 18395994
[TBL] [Abstract][Full Text] [Related]
31. [Thrombophlebitis: bed rest or walking exercise?].
Partsch H
Wien Med Wochenschr; 1999; 149(2-4):50-3. PubMed ID: 10378323
[TBL] [Abstract][Full Text] [Related]
32. Postoperative deep vein thrombosis prophylaxis: a retrospective analysis in 1000 consecutive hip fracture patients treated in a community hospital setting.
Ennis RS
J South Orthop Assoc; 2003; 12(1):10-7. PubMed ID: 12735619
[TBL] [Abstract][Full Text] [Related]
33. Prolonged thromboprophylaxis with dalteparin after surgical treatment of achilles tendon rupture: a randomized, placebo-controlled study.
Lapidus LJ; Rosfors S; Ponzer S; Levander C; Elvin A; Lärfars G; de Bri E
J Orthop Trauma; 2007 Jan; 21(1):52-7. PubMed ID: 17211270
[TBL] [Abstract][Full Text] [Related]
34. Out of hospital antithrombotic prophylaxis after total hip replacement: low-molecular-weight heparin, warfarin, aspirin or nothing? A cost-effectiveness analysis.
Sarasin FP; Bounameaux H
Thromb Haemost; 2002 Apr; 87(4):586-92. PubMed ID: 12008939
[TBL] [Abstract][Full Text] [Related]
35. Cost savings and effectiveness of outpatient treatment with low molecular weight heparin of deep vein thrombosis in a community hospital.
Lee M; Pao D; Hsu T; Sonderskov A
Can J Clin Pharmacol; 2004; 11(1):e17-27. PubMed ID: 15226523
[TBL] [Abstract][Full Text] [Related]
36. An outpatient program to treat deep venous thrombosis with low-molecular-weight heparin.
Pearson SD; Blair R; Halpert A; Eddy E; Mckean S
Eff Clin Pract; 1999; 2(5):210-7. PubMed ID: 10623053
[TBL] [Abstract][Full Text] [Related]
37. The home treatment of deep vein thrombosis with low molecular weight heparin, forced mobilisation and compression.
Labas P; Ohrádka B; Vladimír J; Cambal M
Int Angiol; 2000 Dec; 19(4):303-7. PubMed ID: 11305727
[TBL] [Abstract][Full Text] [Related]
38. Upper extremity deep venous thrombosis in cancer patients with venous access devices--prophylaxis with a low molecular weight heparin (Fragmin).
Monreal M; Alastrue A; Rull M; Mira X; Muxart J; Rosell R; Abad A
Thromb Haemost; 1996 Feb; 75(2):251-3. PubMed ID: 8815570
[TBL] [Abstract][Full Text] [Related]
39. Use of low molecular weight heparin (dalteparin), once daily, for the treatment of deep vein thrombosis. A feasibility and health economic study in an outpatient setting. Swedish Venous Thrombosis Dalteparin Trial Group.
Lindmarker P; Holmström M
J Intern Med; 1996 Dec; 240(6):395-401. PubMed ID: 9010387
[TBL] [Abstract][Full Text] [Related]
40. Practicability and quality of outpatient management of acute deep venous thrombosis.
Blättler W; Kreis N; Blättler IK
J Vasc Surg; 2000 Nov; 32(5):855-60. PubMed ID: 11054216
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
